KLF17 Antibody
Code | Size | Price |
---|
PSI-8041-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-8041-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Storage:
KLF17 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
Images
Documents
Further Information
Additional Names:
Kruppel-like factor 17, zinc finger protein 393, ZNF393, Zfp393
Application Note:
KLF17 antibody can be used for detection of KLF17 by Western blot at 1 - 2 μg/ml. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in rat samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Background:
KLF17, also known as ZNF393, is a member of the Sp/KLF family of transcription factors (1,2). KLF17 binds to the promoter and negatively regulates the transcription of Id-1, a key metastasis regulator in breast cancer (3). Suppression of KLF17 promotes breast cancer cell invasion and epithelial-mesenchymal transition (3). Down-regulated KLF17 expression is also associated tumor invasion and poor prognosis in hepatocellular carcinoma, suggesting that the level of KLF17 expression can serve as a prognostic indicator (4).
Background References:
- Yan W, Burns KH, Ma L, et al. Identification of Zfp393, a germ cell-specific gene encoding a novel zinc finger protein. Mech. Dev. 2002; 118:233-9.
- van Vliet J, Crofts LA, Quinlan KG, et al. Human KLF17 is a new member of the Sp/KLF family of transcription factors. Genomics 2006; 87:474-82.
- Gumireddy K, Li A, Gimotty PA, et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat. Cell Biol. 2009; 11:1297-304.
- Liu FY, Deng YL, Li Y, et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med. Oncol. 2013; 30:425.
Buffer:
KLF17 antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Pig: (81%), Chicken: (79%)
Immunogen:
KLF17 antibody was raised against a 17 amino acid peptide near the carboxy terminus of human KLF17.
The immunogen is located within the last 50 amino acids of KLF17.
The immunogen is located within the last 50 amino acids of KLF17.
NCBI Gene ID #:
128209
NCBI Official Name:
Kruppel-like factor 17
NCBI Official Symbol:
KLF17
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 28, 39, 43 kDa
Observed: 38 kDa
Observed: 38 kDa
Protein Accession #:
NP_775755
Protein GI Number:
104294874
Purification:
KLF17 antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer
SPECIFICITY:
KLF17 antibody is human, mouse and rat reactive. At least two isoforms of KLF17 are known to exist; this antibody will only detect the large isoform. KLF17 antibody is predicted to not cross-react with other KLF proteins.
Swissprot #:
Q5JT82
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | KLF17 Peptide | PSI-8041P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|